Hepatitis Community Educators with AbbVie
Kadmon Corporation KEYS Program Kadmon Enabling Your Success $5 Co-Pay card for RibaPak Visit us online
Gilead R&D has helped transform the treatment of chronic hepatitis C infection and help manage chronic hepatitis B infection.
To discover, develop and deliver innovative medicines that help patients prevail over serious diseases. To our patients and customers, employees, global communities, shareholders, environment and other stakeholders, we promise to act on our belief that the priceless ingredient of...
The FDA has approved the drug Epclusa to treat adult patients with chronic Hep C both with and without cirrhosis.
FDA Expands Daklinza/Sovaldi Approval to Include Treatment of Hep C Genotype 1
The U.S. Food and Drug Administration has approved Zepatier with or without ribavirin for the treatment of chronic Hepatitis C genotypes 1 and 4 infections in adult patients.
DA approved revisions to the Olysio (simeprevir) label to include dosing recommendations for the treatment of HCV/HIV-1 coinfection and to expand the indications and usage to include genotype 4 infection.
YSDOH Drug Utilization Review Board meeting, the board voted to approve Viekira Pak as its preferred drug for persons chronically infected with HCV and enrolled in FFS Medicaid. Viekira Pak will be available for all chronically infected persons regardless of disease severity. Thi...
On Feb 26th, 2015, the NYS Drug Utilization Review Board (DURB) voted unanimously to move Viekira Pak to preferred status for NYS Medicaid Fee-for-service members, and to remove restrictions based on disease prognosis and severity from the current clinical criteria for Viekira Pa...
